CN104208069A - 双炔失碳酯组合物和疾病治疗方法 - Google Patents

双炔失碳酯组合物和疾病治疗方法 Download PDF

Info

Publication number
CN104208069A
CN104208069A CN201410192569.2A CN201410192569A CN104208069A CN 104208069 A CN104208069 A CN 104208069A CN 201410192569 A CN201410192569 A CN 201410192569A CN 104208069 A CN104208069 A CN 104208069A
Authority
CN
China
Prior art keywords
anordrin
certain embodiments
alkyl
agent
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410192569.2A
Other languages
English (en)
Chinese (zh)
Inventor
杨军
施惠娟
徐文平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Planned Parenthood Research
Original Assignee
Shanghai Institute of Planned Parenthood Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Planned Parenthood Research filed Critical Shanghai Institute of Planned Parenthood Research
Priority to CN202110246492.2A priority Critical patent/CN113101292B/zh
Priority to CN202010899146.XA priority patent/CN111956653B/zh
Priority to CN201410192569.2A priority patent/CN104208069A/zh
Publication of CN104208069A publication Critical patent/CN104208069A/zh
Priority to EP15788674.8A priority patent/EP3139928B1/en
Priority to JP2016566286A priority patent/JP6594339B2/ja
Priority to US15/309,426 priority patent/US10231978B2/en
Priority to PCT/CN2015/077942 priority patent/WO2015169173A1/en
Priority to US16/262,617 priority patent/US10857158B2/en
Priority to JP2019089931A priority patent/JP2019142969A/ja
Priority to US16/953,168 priority patent/US11911397B2/en
Priority to JP2020219768A priority patent/JP7084467B2/ja
Priority to JP2022042432A priority patent/JP2022078330A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201410192569.2A 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法 Pending CN104208069A (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN202110246492.2A CN113101292B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法
CN202010899146.XA CN111956653B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法
CN201410192569.2A CN104208069A (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法
PCT/CN2015/077942 WO2015169173A1 (en) 2014-05-08 2015-04-30 Anordrin compositions and methods for treating diseases
JP2016566286A JP6594339B2 (ja) 2014-05-08 2015-04-30 アノルドリン組成物および疾患を処置するための方法
EP15788674.8A EP3139928B1 (en) 2014-05-08 2015-04-30 Anordrin compositions and methods for treating diseases
US15/309,426 US10231978B2 (en) 2014-05-08 2015-04-30 Anordrin compositions and methods for treating diseases
US16/262,617 US10857158B2 (en) 2014-05-08 2019-01-30 Anordrin compositions and methods for treating diseases
JP2019089931A JP2019142969A (ja) 2014-05-08 2019-05-10 アノルドリン組成物および疾患を処置するための方法
US16/953,168 US11911397B2 (en) 2014-05-08 2020-11-19 Anordrin compositions and methods for treating diseases
JP2020219768A JP7084467B2 (ja) 2014-05-08 2020-12-29 アノルドリン組成物および疾患を処置するための方法
JP2022042432A JP2022078330A (ja) 2014-05-08 2022-03-17 アノルドリン組成物および疾患を処置するための方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410192569.2A CN104208069A (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110246492.2A Division CN113101292B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法
CN202010899146.XA Division CN111956653B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法

Publications (1)

Publication Number Publication Date
CN104208069A true CN104208069A (zh) 2014-12-17

Family

ID=52090245

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110246492.2A Active CN113101292B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法
CN202010899146.XA Active CN111956653B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法
CN201410192569.2A Pending CN104208069A (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202110246492.2A Active CN113101292B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法
CN202010899146.XA Active CN111956653B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法

Country Status (5)

Country Link
US (3) US10231978B2 (enExample)
EP (1) EP3139928B1 (enExample)
JP (4) JP6594339B2 (enExample)
CN (3) CN113101292B (enExample)
WO (1) WO2015169173A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015169173A1 (en) * 2014-05-08 2015-11-12 Shanghai Institute Of Planned Parenthood Research Anordrin compositions and methods for treating diseases
CN105279394A (zh) * 2015-10-13 2016-01-27 山西农业大学 用于神经肽受体筛选的方法
WO2019041078A1 (en) * 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
WO2019072014A1 (zh) * 2017-10-13 2019-04-18 上海奥奇医药科技有限公司 含A-失碳-5α雄甾烷化合物的升白制剂及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6788255B2 (ja) * 2015-11-19 2020-11-25 国立大学法人信州大学 新規ベクター及びこれを用いた可溶化タンパク質の製造方法
IL284875B (en) 2016-10-11 2022-07-01 Univ Duke Zofoxifene treatment for breast cancer
US11040054B2 (en) 2016-11-14 2021-06-22 The Brigham And Women's Hospital, Inc. Estrogen sensing through GPER1 regulates normal and malignant liver growth
EP3568132B1 (en) 2017-01-10 2025-12-03 Wang, Wei Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment
EP3773524B1 (en) 2018-04-10 2025-04-09 Duke University Lasofoxifene for the treatment of er+ breast cancer carrying the mutation d538g or y537s
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
US20210299098A1 (en) * 2020-03-31 2021-09-30 Cipla Limited Selective estrogen receptor modulator for treatment of pancreatic cancer
WO2022246634A1 (en) * 2021-05-25 2022-12-01 Zhejiang Jiachi Development Pharmaceuticals Ltd. Compositions for treating insomnia and uses thereof
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101297970A (zh) * 2006-03-17 2008-11-05 山东蓝金生物工程有限公司 同载抗代谢药物及其增效剂的抗癌缓释注射剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001120A (en) * 1989-05-10 1991-03-19 Natural Pharmacia International, Inc. Use of A-Nor-steroids as malignant cells growth inhibitors
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
MXPA05003054A (es) * 2002-09-20 2005-05-27 Pfizer Prod Inc Ligandos de amida y sulfonamida para el receptor de estrogenos.
WO2005048942A2 (en) * 2003-11-13 2005-06-02 Pharmacia Corporation Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
JP2008505079A (ja) * 2004-06-30 2008-02-21 メルク　エンド　カムパニー　インコーポレーテッド エストロゲン受容体調節剤
US20090215731A1 (en) 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
WO2007129062A1 (en) 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
US9220771B2 (en) 2010-07-16 2015-12-29 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases
CN101987081B (zh) * 2010-07-16 2012-08-08 钟术光 一种控释制剂
CN103562226A (zh) 2011-03-11 2014-02-05 梅里麦克制药股份有限公司 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
CN102218069B (zh) * 2011-04-08 2012-09-26 上海奥奇医药科技有限公司 A-失碳-5α-雄甾烷化合物在制备抗恶性肿瘤药物中的应用
CN113101292B (zh) 2014-05-08 2023-07-11 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101297970A (zh) * 2006-03-17 2008-11-05 山东蓝金生物工程有限公司 同载抗代谢药物及其增效剂的抗癌缓释注射剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
徐亮: "具有抗乳腺癌作用的新型芳香化酶抑制剂", 《国外医学药学分册》 *
胥彬等: "双炔失碳酯的抗实验肿瘤作用研究", 《肿瘤》 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015169173A1 (en) * 2014-05-08 2015-11-12 Shanghai Institute Of Planned Parenthood Research Anordrin compositions and methods for treating diseases
US11911397B2 (en) 2014-05-08 2024-02-27 Zhejiang Jiachi Development Pharmaceuticals Ltd Anordrin compositions and methods for treating diseases
US10857158B2 (en) 2014-05-08 2020-12-08 Zhejiang Jiachi Development Pharmaceuticals Ltd Anordrin compositions and methods for treating diseases
US10231978B2 (en) 2014-05-08 2019-03-19 Shanghai Institute Of Planned Parenthood Research Anordrin compositions and methods for treating diseases
CN105279394A (zh) * 2015-10-13 2016-01-27 山西农业大学 用于神经肽受体筛选的方法
CN105279394B (zh) * 2015-10-13 2017-12-26 山西农业大学 用于神经肽受体筛选的方法
CN111050771A (zh) * 2017-08-28 2020-04-21 浙江嘉驰医药开发有限公司 不对称合成及化合物在疾病治疗中的应用
WO2019042192A1 (en) * 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
CN111050771B (zh) * 2017-08-28 2023-08-01 浙江嘉驰医药开发有限公司 不对称合成及化合物在疾病治疗中的应用
CN117281816A (zh) * 2017-08-28 2023-12-26 浙江嘉驰医药开发有限公司 不对称合成及化合物在疾病治疗中的应用
WO2019041078A1 (en) * 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
US12403115B2 (en) 2017-08-28 2025-09-02 Zhejiang Jiachi Development Pharmaceuticals Ltd Asymmetric synthesis and uses of compounds in disease treatments
CN109662968A (zh) * 2017-10-13 2019-04-23 上海奥奇医药科技有限公司 含A-失碳-5α雄甾烷化合物的升白制剂及其应用
WO2019072014A1 (zh) * 2017-10-13 2019-04-18 上海奥奇医药科技有限公司 含A-失碳-5α雄甾烷化合物的升白制剂及其应用
CN109662968B (zh) * 2017-10-13 2021-05-18 上海奥奇医药科技有限公司 含A-失碳-5α雄甾烷化合物的升白制剂及其应用
AU2018348892B2 (en) * 2017-10-13 2022-01-27 Shanghai Ao Qi Medical Technology Co., Ltd. Formulation containing A-decarbonized-5a androstane compound for increasing white blood cell and use thereof

Also Published As

Publication number Publication date
CN113101292A (zh) 2021-07-13
WO2015169173A1 (en) 2015-11-12
EP3139928B1 (en) 2025-03-05
EP3139928C0 (en) 2025-03-05
US10857158B2 (en) 2020-12-08
US10231978B2 (en) 2019-03-19
JP2017514853A (ja) 2017-06-08
JP2022078330A (ja) 2022-05-24
CN111956653A (zh) 2020-11-20
JP7084467B2 (ja) 2022-06-14
JP2021050241A (ja) 2021-04-01
CN113101292B (zh) 2023-07-11
US20170151263A1 (en) 2017-06-01
US11911397B2 (en) 2024-02-27
JP6594339B2 (ja) 2019-10-23
EP3139928A4 (en) 2017-12-13
JP2019142969A (ja) 2019-08-29
US20190262360A1 (en) 2019-08-29
US20210069212A1 (en) 2021-03-11
EP3139928A1 (en) 2017-03-15
CN111956653B (zh) 2023-06-30

Similar Documents

Publication Publication Date Title
US11911397B2 (en) Anordrin compositions and methods for treating diseases
CN115737636B (zh) 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
Motiani et al. Orai3 is an estrogen receptor α-regulated Ca2+ channel that promotes tumorigenesis
US20090124587A1 (en) METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
EP3213752B1 (en) Composition for treating cancer stem cells
CN107614062A (zh) 用RORγ抑制剂治疗癌症的方法
Xu et al. Astemizole promotes the anti-tumor effect of vitamin D through inhibiting miR-125a-5p-meidated regulation of VDR in HCC
AU2014207272A1 (en) Estrogen receptor inhibitors
Tan et al. Hsp90 Inhibitor STA9090 induced VPS35 related extracellular vesicle release and metastasis in hepatocellular carcinoma
Zhan et al. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways
Li et al. Usenamine A triggers NLRP3/caspase-1/GSDMD-mediated pyroptosis in lung adenocarcinoma by targeting the DDX3X/SQSTM1 axis
CN116036094B (zh) 一种Rab13基因和EGFR蛋白表达的抑制剂及应用
Jindal et al. Milciclib and sorafenib synergistically downregulate c-Myc to suppress tumor growth in an orthotopic murine model of human hepatocellular carcinoma
Gorska‑Ponikowska et al. of mitochondrial dynamics in 2‑methoxyestradiol‑mediated osteosarcoma cell death
Sabnis et al. In Vivo Models of AI Resistance
HK1241730A1 (en) Composition for treating cancer stem cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141217